

June 7, 2023  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

**Onconova Therapeutics Announces Poster Presentation  
at the 2023 American Society of Clinical Oncology Annual Meeting**

TOKYO, Japan, June 7, 2023 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that its U.S. licensor for rigosertib, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova"), on June 5, 2023 (EST) announced the presentation of a poster detailing the design of its ongoing investigator-sponsored clinical trial evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) at the 2023 American Society of Clinical Oncology ("ASCO") Annual Meeting, held from June 2-6, 2023 in Chicago, Illinois.

For Onconova's full press release, please visit Onconova's website: <https://investor.onconova.com/press-releases>

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

### **About rigosertib**

Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activation of RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K, and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus killing cancer cells. SymBio obtained the development and commercialization licensing rights for rigosertib from Onconova in July 2011 for Japan and Korea.

### **About Onconova Therapeutics, Inc.**

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

For more information, please visit <https://www.onconova.com>

### **About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Carolyn Yanavich).

The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.